Prieto 2008.
| Methods | Randomised, controlled single centre study | |
| Participants | 46 patients (23 doxazosin, 23 no treatment), mean age 74 years | |
| Interventions | A (23): Doxazosin modified release 4 mg once daily B (23): No treatment TWOC on day 32. |
|
| Outcomes | TWOC success rates: A 13/22, B 13/24 Maximum urinary flow rate in patients with spontaneous micturition Post‐void residual volume in patients with spontaneous micturition |
|
| Notes | Second phase trial: successful TWOC patients review at 6, 12 and 24 months for recurrence of AUR | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | 'Two groups were formed.' Patients 'born in even‐numbered years' (doxazosin group) versus 'born in odd‐numbered years' (no treatment group) |
| Allocation concealment (selection bias) | High risk | Patients 'born in even‐numbered years' (doxazosin group) versus 'born in odd‐numbered years' (no treatment group) |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No incomplete data |
| Selective reporting (reporting bias) | Unclear risk | All the outcomes as detailed in the method section of the trial were reported in the result section. Some outcomes which are considered important from patients’ perspective were not reported. Without the protocol it was difficult to judge whether or not these outcomes were included in the protocol and not reported in the report. |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Blinding is unlikely given the study design. |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not specified |
| Other bias | High risk | High risk:
Low risk:
|